Inovio Pharmaceuticals, Inc. (INO)
USD 1.78
(-9.18%)
USD 1.78
(-9.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 832.01 Thousand | 10.26 Million | 1.77 Million | 7.41 Million | 4.11 Million | 30.48 Million |
| Cost of Revenue | 3.5 Million | 5.49 Million | 4.73 Million | 94.24 Million | 88.01 Million | - |
| Gross Profit | -2.67 Million | 4.76 Million | -2.95 Million | -86.83 Million | -83.9 Million | 30.48 Million |
| Operating Expenses | 132.55 Million | 277.83 Million | 302.99 Million | 131.49 Million | 115.22 Million | 124.57 Million |
| Selling, General and Administrative Expenses | 47.58 Million | 90.18 Million | 53.75 Million | 37.24 Million | 27.2 Million | 29.31 Million |
| Research and Development Expenses | 88.47 Million | 187.65 Million | 249.24 Million | 94.24 Million | 88.01 Million | 95.25 Million |
| Other Expenses | -3.5 Million | -3.86 Million | 343.37 Thousand | 3.41 Million | 496.2 Thousand | 360.79 Thousand |
| Cost and Expenses | 136.05 Million | 277.83 Million | 302.99 Million | 131.49 Million | 115.22 Million | 124.57 Million |
| Operating Income | -135.22 Million | -267.57 Million | -301.21 Million | -124.08 Million | -111.1 Million | -94.09 Million |
| Interest Expense | 1.22 Million | 1.25 Million | 1.93 Million | 8.7 Million | 7.94 Million | 346.08 Thousand |
| Income Tax Expense | - | 10.01 Million | 2.16 Million | 52.19 Million | -257.33 Thousand | 2.16 Million |
| Earnings before Tax | -135.11 Million | -277.65 Million | -303.22 Million | -162.89 Million | -120.8 Million | -94.79 Million |
| Net Income | -135.11 Million | -287.66 Million | -305.38 Million | -215.08 Million | -120.55 Million | -96.96 Million |
| Earnings Per Share Basic | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 |
| Earnings Per Share Diluted | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 |
| Weighted Average Shares Outstanding | 22.17 Million | 19.88 Million | 17.4 Million | 12.92 Million | 8.22 Million | 92.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 22.17 Million | 19.88 Million | 17.4 Million | 12.92 Million | 8.22 Million | 92.53 Million |
| Gross Margin | -3.21 | 0.46 | -1.67 | -11.72 | -20.41 | 1.00 |
| EBIT Margin | -156.72 | -26.17 | -165.28 | -10.28 | -25.68 | -2.93 |
| Profit Margin | -162.40 | -28.03 | -172.07 | -29.02 | -29.32 | -3.18 |
| EBITDA | -130.39 Million | -270.9 Million | -296.55 Million | -149.56 Million | -107.34 Million | -89.8 Million |
| Earnings Before Tax Margin | -162.53 | -26.07 | -169.72 | -16.74 | -27.02 | -3.09 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 100.76 Thousand | - | 832.01 Thousand | 102.65 Thousand | 388.44 Thousand | 225.97 Thousand |
| Cost of Revenue | 828.62 Thousand | 759.73 Thousand | 3.5 Million | 175.22 Thousand | 1.03 Million | 1.14 Million |
| Gross Profit | -727.86 Thousand | -759.73 Thousand | -2.67 Million | -72.57 Thousand | -644.32 Thousand | -917.43 Thousand |
| Operating Expenses | 32.46 Million | 30.72 Million | 132.55 Million | 27.32 Million | 35.94 Million | 37.26 Million |
| Selling, General and Administrative Expenses | 9.37 Million | 9.81 Million | - | 10.06 Million | 9.92 Million | 13.52 Million |
| Research and Development Expenses | 23.09 Million | 20.91 Million | - | 17.25 Million | 15.5 Million | 23.74 Million |
| Other Expenses | 7571.00 | -682.21 Thousand | -4.71 Million | -860.9 Thousand | 10.51 Million | -1.42 Million |
| Cost and Expenses | 33.29 Million | 31.48 Million | 136.05 Million | 27.49 Million | 35.94 Million | 37.26 Million |
| Operating Income | -33.19 Million | -31.48 Million | -135.22 Million | -27.39 Million | -35.55 Million | -37.04 Million |
| Interest Expense | - | 177.83 Thousand | 1.22 Million | 282.32 Thousand | -313.48 Thousand | 313.48 Thousand |
| Income Tax Expense | 5.00 | 716.45 Thousand | 2.00 | 3.00 | -1.03 Million | -957.63 Thousand |
| Earnings before Tax | -32.23 Million | -30.46 Million | -135.11 Million | -25 Million | -33.92 Million | -35.53 Million |
| Net Income | -32.23 Million | -30.46 Million | -135.11 Million | -25 Million | -33.92 Million | -35.53 Million |
| Earnings Per Share Basic | -1.19 | -1.31 | - | -1.10 | -1.52 | -1.61 |
| Earnings Per Share Diluted | -1.19 | -1.31 | - | -1.10 | -1.52 | -1.61 |
| Weighted Average Shares Outstanding | 27.19 Million | 23.29 Million | 22.17 Million | 22.79 Million | 22.38 Million | 22.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 27.19 Million | 23.29 Million | 22.17 Million | 22.79 Million | 22.38 Million | 22.02 Million |
| Gross Margin | -7.22 | - | -3.21 | -0.71 | -1.66 | -4.06 |
| EBIT Margin | -321.23 | - | - | -265.16 | -91.53 | -154.89 |
| Profit Margin | -319.93 | - | -162.40 | -243.58 | -87.35 | -157.25 |
| EBITDA | -32.36 Million | -30.72 Million | - | -27.21 Million | -35.55 Million | -35 Million |
| Earnings Before Tax Margin | -329.46 | - | -162.53 | -266.86 | -91.53 | -163.92 |
WMELF
INBI
NEXE
CEEJAY
JSHL
PLUS